mFOLFOX 6
Phase 3Small molecule
Boehringer IngelheimmFOLFOX 6 is one of 67 small molecule programs targeting Esophagus Adenocarcinoma. It is currently in Phase 3.
3
Indications
10
Total Trials
5
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
268 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1Stivarga
BayerPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Acetylsalicylic Acid
BayerPhase 3
Trifluridine/tipiracil
AbbViePhase 3
Telisotuzumab Adizutecan
AbbViePhase 3
XL092
RochePhase 3
TAS 102
Taiho Oncology, Inc.Phase 3
5-Fu
TToray Industries, Inc
Phase 3
PD-1 Monoclonal Antibody
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer2 trials
4 more indications
Adenocarcinoma1 trial
Stage III Colon Cancer1 trial
Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer
Recruiting·—·Phase 2/3·NCT05179889·308 enrolled
Resectable1 trial
Esophagus Adenocarcinoma1 trial
Organ Preservation With Durvalumab-based Immunotherapy in Combination With Chemoradiation as Definitive Therapy for Early Stage, cT1 and cT2N0, Esophageal Adenocarcinoma With Indication for Radical Surgery: A Prospective, Multicenter Study of the FLOT-AIO Gastric Cancer Group
Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05713838·32 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mFOLFOX 6. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company